ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 992

The Impact of Inflammatory Arthritis (rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, reactive arthritis) on Maternal and Neonatal Outcomes: A Population-Level Analysis

Stephanie Keeling1, Anamaria Savu2 and Padmaja Kaul3, 1Department of Medicine, Division of Rheumatology, Edmonton, AB, Canada, 2Canadian Vigour Center, Edmonton, AB, Canada, 3Cardiology, University of Alberta, Edmonton, AB, Canada

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: inflammatory arthritis, population studies, pregnancy and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Epidemiology and Public Health I: Inflammatory Arthritis – Risk and Impact

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose:  The impact of inflammatory arthritis (IA) including rheumatoid (RA), psoriatic (PsA), and spondyloarthritis (SpA) on maternal, obstetrical and neonatal outcomes is not well described at the population level. Accordingly, we compared maternal and neonatal outcomes of women with and without IA in a contemporary pregnancy-birth cohort in a defined geographic area (province of Alberta, Canada) with universal health care.

Methods:  The patient population consisted of 316,458 women who delivered singleton, live babies between 01/01/05 and 12/31/2014. Only the first birth for each woman during the study time period was included in the analysis. Previously established International Classification of Disease (ICD) version 9 or 10 was used to identify women with IA. A woman was considered to have IA if the diagnosis was present in a hospitalization, or in two outpatient records within 2 years that were at least 2 months apart. Women with IA were further categorized as RA and other IA . Other IA included psoriatic arthritis, spondyloarthritis, and reactive arthritis. Psoriasis patients were included in “other IA” due to the overlapping ICD 9/10 codes between PsO and PsA.

Results:  There were 577 women with RA; 2281 with other IA; and 313600 with neither. Although statistically significantly different, maternal age did not differ substantially across groups (Table 1). Babies of women with RA were more likely to be small for gestational age (SGA). Maternal and neonatal outcomes in the other IA group were similar to those in women with neither disease (no IA). Rates of caesarean section and preterm delivery were significantly higher among women with RA (Table 1).

Conclusion: Our study provides novel data on the prevalence of RA and other IA in a contemporary cohort of pregnant women. We find that RA is associated with a higher likelihood of undergoing a caesarean section, preterm delivery and of having an SGA infant; however, other IA had no impact on maternal and neonatal outcomes. Our study highlights the need for peripartum counselling of women with RA.

Neonatal Outcome No Inflammatory Arthritis Rheumatoid Arthritis Other Inflammatory Arthritis P-value
Mean Maternal Age (years) (SD) 28.6 (5.6) 29.9 (5.7) 29.4 (5.4) <0.0001
Mean Birthweight (grams) (SD) 3335.7 (565.6) 3203.1 (592.8) 3348.5 (563.0) <0.0001
Small for gestational age (SGA) (n (%)) 37826 (12.1%) 93 (16.1%) 261 (11.5%) 0.0074
Preterm Delivery (< 37 weeks) (n (%)) 22779 (7.3%) 85 (14.7%) 170 (7.5%) <0.0001
Caesarean section (n (%)) 87956 (28.0) 196 (34.0) 665 (29.2) <0.001

TABLE 1. Neonatal outcomes in Albertan women with “no inflammatory arthritis” (no IA), “rheumatoid arthritis” (RA) and “other inflammatory arthritis” (psoriatic arthritis, psoriasis, spondyloarthritis, reactive arthritis)


Disclosure: S. Keeling, None; A. Savu, None; P. Kaul, None.

To cite this abstract in AMA style:

Keeling S, Savu A, Kaul P. The Impact of Inflammatory Arthritis (rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, reactive arthritis) on Maternal and Neonatal Outcomes: A Population-Level Analysis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/the-impact-of-inflammatory-arthritis-rheumatoid-arthritis-spondyloarthritis-psoriatic-arthritis-reactive-arthritis-on-maternal-and-neonatal-outcomes-a-population-level-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-inflammatory-arthritis-rheumatoid-arthritis-spondyloarthritis-psoriatic-arthritis-reactive-arthritis-on-maternal-and-neonatal-outcomes-a-population-level-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology